Remofuscin has the surprising characteristic of removing lipofuscin from living cells in the retinal pigment epithelium (RPE). This paradigm-breaking effect was previously believed to be impossible.
Remofuscin is being developed for two indications: Stargardt disease and dry age-related macular degeneration. In both indications, Remofuscin is entering Phase 2.
For the purpose of being contacted by Katairo upon important news, you may provide your e-mail contact information below.